Dr. Selwyn Ho is a seasoned Pharma and Biotech leader with extensive experience in commercial strategy, corporate leadership, financing, and board governance. As a trained medical doctor with a track record spanning multiple commercial roles, he now serves as CEO of Medigene AG, a publicly traded immuno-oncology company. In this role, he has led a strategic transformation, streamlining R&D, securing key partnerships with BioNTech, Regeneron, and WuXi Biologics, and successfully driving financing rounds.

Previously, as EVP & Chief Business Officer at Connect Biopharma, Dr. Ho played a key role in raising $220 million through an IPO and securing $135 million in private financing. His leadership experience includes senior roles at Dermira (Eli Lilly), UCB, Allergan (AbbVie), Novartis, and AstraZeneca, providing him with deep expertise in commercialization, market access, and global product strategy across immunology, oncology, and dermatology. Dr. Ho also brings strong board experience, currently serving as a Non-Executive Director at Antennova Inc. and Peptomyc S.L., and as an Executive-in-Residence at New Rhein Healthcare Investors. Dr. Ho received his medical degree (MB, BS) and Bachelor of Science (BSc) in Pharmacology from Imperial College, University of London, UK, and post-graduate qualifications (Dip Pharm Med) in Pharmaceutical Medicine from the Faculty of Pharmaceutical Physicians, Royal College of Physicians, UK.